cystopurin - परिणामों की खोज

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

d-penamine

viatris limited - penicillamine 250mg - tablet - 250 mg - active: penicillamine 250mg excipient: glycerol hypromellose microcrystalline cellulose povidone purified water sodium starch glycolate stearic acid titanium dioxide - severe, active rheumatoid arthritis. as a chelating agent in the treatment of wilson's disease and lead poisoning. d-penamine will enhance the urinary excretion of gold and mercury and other heavy metals. in the treatment of cystinuria in cases where high-fluid regimens are not adequate, or in conjunction with them.

इसराइल - अंग्रेज़ी - Ministry of Health

cystadane

medison pharma ltd - betaine anhydrous - powder for solution - betaine anhydrous 1 g/g - betaine - treatment of homocystinuria.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

cystadane- betaine, anhydrous powder, for solution

jazz pharmaceuticals, inc. - betaine, anhydrous (unii: 3scv180c9w) (betaine, anhydrous - unii:3scv180c9w) - powder, for solution - 180 g in 1 g - cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are deficiencies or defects in: - cystathionine beta-synthase (cbs), - 5,10-methylenetetrahydrofolate reductase (mthfr), - cobalamin cofactor metabolism (cbl ). patient response to cystadane can be monitored by homocysteine plasma levels (see dosage and administration). response usually occurs within a week and steady state within a month. cystadane has been administered concomitantly with vitamin b6 (pyridoxine), vitamin b12 (cobalamin), and folate.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

cystadane

pharmacy retailing (nz) ltd t/a healthcare logistics - betaine 180 g - powder for oral solution - 1 g - active: betaine 180 g - indicated as an adjunct in the treatment of homocystinuria. indicated to decrease elevated homocysteine blood levels in patients of all age groups with: 1. cystathionine beta-synthase (cbs deficiency) type homocystinuria, or 2. 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency), or 3. cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria. indicated to increase methionine and s-adenosylmethionine blood levels in patients with 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency) and cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

thiola- tiopronin tablet, sugar coated

mission pharmacal company - tiopronin (unii: c5w04go61s) (tiopronin - unii:c5w04go61s) - tiopronin 100 mg - thiola ® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine. cystine stones typically occur in approximately 10,000 persons in the united states who are homozygous for cystinuria. these persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). in addition, they show varying intestinal transport defects for these same amino acids. the stone formation is the result of poor aqueous solubility of cystine. since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. cystine solubility in urine is ph-dependent, and ranges from 170-300 mg/liter at ph 5, 190-400 mg/liter at ph 7 and 220-500 mg/liter at ph 7.5. the goal of therapy is to reduce urinary cystine concentration below its solubility limit. it may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). in such patients, d-penicillamine has been used as an additional therapy. like thiola ™ , dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine. however, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. thiola ® may have a particular therapeutic role in such patients. the use of thiola ® during pregnancy is contraindicated, except in those with severe cystinuria where the anticipated benefit of inhibited stone formation clearly outweighs possible hazards of treatment (see precautions). thiola ® should not be begun again in patients with a prior history of developing agranulocytosis, aplastic anemia or thrombocytopenia on this medication. mothers maintained on thiola ® treatment should not nurse their infants.